Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Thiamet G in O-GlcNAcase Inhibition: Beyond Neurodegeneratio
2026-06-12
Discover how Thiamet G, a potent O-GlcNAcase inhibitor, is advancing research on ferroptosis, trophoblast biology, and tauopathy. This article uniquely explores the intersection of O-GlcNAcylation modulation and disease modeling, highlighting novel translational opportunities.
-
Phillygenin Mitigates Diabetic Nephropathy via Inflammatory
2026-06-12
This study demonstrates that phillygenin, a bioactive compound from Forsythia suspensa, reduces inflammation and apoptosis in diabetic nephropathy by targeting the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. The findings offer mechanistic insight into phillygenin's therapeutic potential for diabetic kidney injury and support the use of fluorescence-based cell viability assays in mechanistic research.
-
Polyphosphazene Nanoparticles: Spermine Crosslinking for Pro
2026-06-11
This study demonstrates how ionic polyphosphazene nanoparticles, cross-linked with spermine tetrahydrochloride, efficiently encapsulate proteins while preserving their activity and modulating cellular interactions. The findings advance nanoparticle engineering for therapeutic delivery, highlighting key differences between soluble and nanoparticulate formulations.
-
SMYD2 Inhibition Attenuates Drug Resistance in Renal Cell Ca
2026-06-11
The referenced study identifies SMYD2 as a critical epigenetic regulator of multidrug resistance and tumor progression in clear cell renal cell carcinoma (ccRCC). By mechanistically linking SMYD2 to microRNA-125b and P-glycoprotein (P-gP) pathways, the research highlights new avenues for overcoming chemoresistance in aggressive renal cancers.
-
SD 169 (indole-5-carboxamide): Mechanistic Precision in p38
2026-06-10
Explore how SD 169 (indole-5-carboxamide) uniquely enables precise modulation of p38 MAPK dephosphorylation, advancing type 1 diabetes and neuroregeneration research. This article offers a mechanistic analysis and practical assay insights not found in existing reviews.
-
PD0325901: MEK Inhibitor Workflows for Cancer Pathway Resear
2026-06-10
PD0325901 from APExBIO empowers researchers to dissect the RAS/RAF/MEK/ERK pathway with precision, enabling robust apoptosis and cell cycle arrest studies. This guide translates cutting-edge findings and product nuances into optimized protocols and troubleshooting strategies for impactful oncology research.
-
Selective Spectrophotometric Analysis for β-Lactam Antibioti
2026-06-09
This study introduces two selective spectrophotometric methods for quantifying phenolic β-lactam antibiotics, including their combinations with penicillin-class agents like dicloxacillin. The approaches enable practical, robust analysis in pharmaceutical research, with direct implications for MSSA-targeted antibiotic studies.
-
PNU 74654: Precision Wnt Signaling Pathway Inhibitor Workflo
2026-06-09
PNU 74654 empowers researchers to dissect Wnt/β-catenin signaling with high specificity, supporting advanced cancer and stem cell research. This guide translates landmark findings into hands-on protocols, troubleshooting advice, and advanced applications for robust, reproducible results.
-
E. coli Uracil-DNA Glycosylase (UDG): Technical Use and Prot
2026-06-08
E. coli Uracil-DNA Glycosylase (UDG) is designed for precise removal of uracil from DNA templates, addressing PCR product contamination and supporting DNA repair enzyme research. It is not suitable for RNA substrates, oligonucleotides shorter than six bases, or any diagnostic or clinical use.
-
Stattic: STAT3 Inhibitor Workflows for Cancer Cell Assays
2026-06-08
Stattic’s selective inhibition of STAT3 dimerization empowers researchers to dissect cancer pathways and radiosensitization mechanisms with precision. Explore protocol optimizations, troubleshooting, and real-world insights from recent breakthroughs in STAT3-driven lymphangiogenesis and apoptosis induction in cancer cells.
-
Fluorouracil in Solid Tumor Research: Advanced Protocols & S
2026-06-07
Fluorouracil (Adrucil) delivers reproducible inhibition of DNA replication for colon and breast cancer research, with robust workflows for both in vitro and in vivo studies. This guide details advanced protocol enhancements, troubleshooting strategies, and actionable insights to maximize the scientific impact of APExBIO’s validated reagent.
-
ORAI2-Driven SOCE Promotes Early Salivary Gland Fibrosis Pos
2026-06-06
The reference study delineates ORAI2 as a pivotal driver of early-stage postirradiation fibrosis in salivary glands, mapping a novel ORAI2/JNK/NFAT1/TGF-β1 axis. These findings clarify calcium-mediated mechanisms in radiation-induced tissue damage and highlight new molecular targets for mitigating hyposalivation and fibrosis after radiotherapy.
-
Patient-Derived Gastric Cancer Assembloid Models Advance Dru
2026-06-05
This study presents a novel patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations. The approach closely mirrors primary tumor complexity and reveals how stromal elements modulate drug responses, offering new precision tools for preclinical and personalized therapy research.
-
Parathyroid hormone (1-34) (human): Applied Workflows and In
2026-06-05
Parathyroid hormone (1-34) (human) unlocks high-fidelity modeling of bone and kidney function, powering cutting-edge disease research. This guide distills experimental protocols, troubleshooting insights, and actionable workflow enhancements, bridging bench success and translational impact.
-
WP1066, JAK2/STAT3 Inhibitor, Cell-Permeable: Reliable Assay
2026-06-04
This article addresses common laboratory challenges in cell-based assays and translational cancer research, focusing on evidence-based deployment of WP1066, JAK2/STAT3 inhibitor, cell-permeable (SKU A4140). Drawing on recent literature and validated protocols, we guide biomedical researchers toward reproducible, sensitive results in proliferation, cytotoxicity, and regenerative workflows.